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Summary 
Up to 50% of patients with autoimmune diseases show an impairment of health-
related quality of life and exhibit depression-like symptoms. The immune system 
not only leads to inflammation in affected organs, but also mediates behavior 
abnormalities including fatigue and depression-like symptoms.  This review 
focuses on the different pathways involved in the communication of the immune 
system with the neuronal network and the body’s timing system. The latter is 
built up by a hierarchically organized expression of clock genes. As discussed 
here, the activation of the immune system interferes with high amplitude 
expression of clock genes, an effect which may play a pivotal role in depression- 
like behavior in autoimmune diseases.  
 
 
1. Introduction 
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In autoimmune diseases, psychological symptoms, such as fatigue, loss of 
interest in daily activities, and cognitive deficits, are common. Whilst these 
symptoms are often described as sickness behaviour, they are also core 
symptoms in the diagnosis of depression. This raises a number of issues, and 
perhaps most important is the issue of whether sickness behaviour and 
depression are one and the same, or do they have fundamentally different 
pathophysiologies so that it is more appropriate to regard them as separate 
clinical states? The present chapter reviews the evidence for inflammation in 
depression and for depression-like symptoms in autoimmune diseases. It is not 
currently possible to unequivocally answer the issues raised above. However, we 
do provide an overview of some of the most relevant evidence that can inform 
this controversial, interesting and medically important debate.  
 
Patients with depression, most notably major depressive disorder (MDD), who 
are otherwise medically healthy have been found to exhibit features of immune 
activation. Increases of the circulating cytokines interleukin (IL)-6 and tumor 
necrosis factor alpha (TNF), their soluble receptors, and the acute phase protein, 
C-reactive protein (CRP), have been reported (Dowlati et al., 2010); for review 
see: (Felger and Lotrich, 2013; Miller et al., 2009). Moreover, gene expression 
profiling conducted on post-mortem brain tissue samples from the frontal cortex 
of patients with MDD shows an upregulated expression of cytokines including eg 
IL-1, IL-18, IL-8, IL-12, lymphotoxin alpha and interferon (IFN)- (Shelton et al., 
2011). More direct evidence for the involvement of cytokines in the 
pathophysiology of MDD comes from the observations that (i) anti-TNF 
treatment has therapeutic effects in resistant MDD with increased CRP (Raison et 
al., 2013), and (ii) the development of depressed mood, anxious symptoms and 
impaired cognition in human patients treated with type I interferons ((Miller et 
al., 2009)). Likewise, in mice, the systemic or intracerebroventricular 
administration of cytokines or cytokine inducers leads to depressive-like 
behavior (Fu et al., 2010). Pathways that translate the cytokine signals from the 
periphery to the brain involve (i) actions of cytokines on the vagal nerve and 
activation of Toll-like receptors in circumventricular organs, (ii) interactions of 
cytokines with the hypothalamic-pituitary-adrenal axis, and (iii) cytokine 
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triggered activation of indoleamine-2,3-dioxygenase leading to tryptophan 
catabolism and decreased serotonin concentrations in the central nervous 
system (CNS) (for review see (Dantzer et al., 2008; Haroon et al., 2012).  
 
In light of the putative causal link of increased cytokines and depression, we may 
ask whether depression-like symptoms or depression per se is also a hallmark in 
autoimmune diseases. The latter are characterized by anti-self T- and B-cell 
reactivity, which leads to organ dysfunction due to destruction of parenchymal 
cells in various organs, including kidney, lung, liver, intestinal tract and the 
peripheral and central nervous systems. The immune response towards 
autoantigens is characterized by activation of neutrophils, monocytes-
macrophages, dendritic cells and lymphocytes on the one hand, and decreased 
activity of negative feedback loops provided by regulatory T- and B- cells and by 
suppressive macrophages, on the other. Both the priming and effector phases of 
the autoimmune response are associated with increased production of cytokines. 
Since inducers of cytokines and cytokines per se induce depressive-like behavior 
in both experimental animal models and humans it is not surprising that 
autoimmune diseases have also been associated with depression. In the 
following we will focus on the evidence for depression-like symptoms in 
autoimmune diseases and animal models thereof. We will concentrate on 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), since in 
these diseases large cohort studies on mental health have been conducted and 
therefore a relatively amount of data  are available. However, depression-like 
symptoms have also been well described in many other autoimmune diseases 
including multiple sclerosis and inflammatory bowel disease (for review see 
(Greenley et al., 2010; Marrie et al., 2015)). Moreover, depression-like symptoms 
are also a hallmark of autoinflammatory diseases. These inherited diseases are 
characterized by inadequate activation of the immune system with production of 
cytokines due to mutations in genes encoding for the inflammasome. The most 
frequent form is familial Mediterranean fever (FMF), which develops due to 
mutations of the pyrin/FMF gene. In FMF patients depression-like behavior is 
seen frequently; the depression-like symptom severity does not depend on FMF 
duration, but rather on the FMF severity score (Makay et al., 2010). 
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2. Depression-like symptoms in systemic lupus erythematosus 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
loss of tolerance, which is associated with production of autoantibodies and 
immune-mediated injury resulting in tissue damage in various organs including 
kidney, lung, skin and central nervous system. Activation of the complement 
system by immune complexes leads to endothelial cell disruption. SLE takes a 
relapsing-remitting disease course which, depending on the affected organ can 
be mild or severe. Numerous studies show that patients with SLE have a 
significantly poorer health-related quality of life (HRQoL) and exhibit 
depression-like symptoms more often than do healthy controls. In a systematic 
literature search 17 studies were identified that reported on depression 
comorbidity symptoms, with prevalence a rate of 17-75% depending on study 
(Palagini et al., 2013). Different methods were used to assess depression across 
these studies, and this is likely to contribute to the wide range in the prevalence 
reported.  
 
A study on 170 SLE patients found HRQoL to be negatively influenced mainly by 
disease activity and depression (Shen et al., 2014). Both parameters were 
associated with higher levels of pain and fatigue (Pettersson et al., 2012; 
Waldheim et al., 2013). Using the Beck Depression Inventory (BDI) patients with 
SLE had a higher score compared with the general population from a pan-Europe 
population based study (van Exel et al., 2013). The prevalence of depression was 
found to be 16.6% in SLE and 6.7% in controls. There was no association 
between disease activity and organ damage. Likewise in 113 patients with SLE 
no relationship between HRQoL and SLE activity or disease duration was 
observed (Yilmaz-Oner et al., in press). In 110 lupus patients the SLE activity 
index did correlate with the anxiety score, but not with depression (Tay et al., 
2015). Another study using BDI-II showed 53 of 127 SLE patients (41.7%) to 
have moderate or severe depressive symptoms (Karol et al., 2013). When 
assessing sleep behavior in 81 patients with SLE, depressive symptoms were 
associated significantly with poor sleep quality, and cognitive deficits occurred in 
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16 of 82 patients (Palagini et al., 2014). Impaired cognitive performance in 
sustained attention and spatial working memory tests was related to SLE, but 
not to depression (Calderon et al., 2014). With respect to the important question 
of whether depression-like symptoms in autoimmune-disease patients results in 
poorer disease control, in general it is indeed thought that depression is 
associated with increased disease activity, decreased medication adherence, and 
decreased work productivity (Bachen et al., 2009; Panopalis et al., 2008).  
 
Approximately 15-20% of SLE cases begin in childhood, at a median age of onset 
of 12-13 years. In children and adolescents with SLE (n= 38) and young adults 
with childhood-onset of disease (n=16), depression was observed in 26% and 
44% of the patients, respectively (Ahola Kohut et al., 2013). Depression was not 
correlated with disease duration, HRQoL or SLE nephritis. In pediatric lupus and 
mixed connective tissue disease, depression was associated with poor disease 
control; non-Caucasian patients were at significantly higher risk for depression-
like symptoms than Caucasian patients (Knight et al., 2015; Knight et al., 2014). 
In general disease scores, lupus nephritis and involvement of the central nervous 
system - neuropsychiatric lupus (NPSLE) - takes a more aggressive course in 
African-Americans. In this group of patients, higher perceived racism was 
associated with having moderate to severe depression (Vina et al., 2015). 
Suicidal ideation has been observed in pediatric lupus with NPSLE in 34% of 53 
patients, and 20% of those with ideation attempted suicide (Lim et al., 2013). In 
adults with SLE, suicidal ideation is common in up to one-third of patients with 
and without NPSLE, and is associated with higher disease activity, increased 
depression and anxiety severity and previous suicide attempts (Karassa et al., 
2003; Mok et al., 2014; Xie et al., 2012). 
 
The mechanisms underlying depression or depression-like symptoms in SLE are 
not yet clear, but are likely to be multifactorial. The burden of having a chronic 
illness, the use of corticosteroids and immunosuppressive drugs for disease 
control and prevention of disease, microvasculopathy as well as the development 
of secondary cerebrovascular injury due to hypertension, hyperlipidemia and 
anti-phospholipid antibodies, may all constitute risk factors in SLE.  Depression 
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in women with SLE (n=161) correlates with the presence of cardiovascular 
disease (Greco et al., 2012). Serum TNF was found to be higher in SLE (n=54) 
compared to controls. Interestingly, increased TNF was associated with more 
severe depression-like symptoms as evaluated by the Hospital Anxiety and 
Depressive Scale (HADs) (Mak et al., 2013). Injection of TNF in rodents leads to 
sickness behavior and depression-like behavior (Fu et al., 2010). Patients with 
SLE exhibit high serum levels of IFN type I and overexpress IFN-I-stimulated 
genes in peripheral blood cells. The increased IFN-I signature is associated with 
active disease including lupus nephritis. Since in patients with multiple sclerosis 
or hepatitis C, treatment with IFN- induces depression and the risk of suicidal 
ideation, the endogenous expression of IFN-I in SLE may contribute to 
depression-like symptoms. However, in patients with SLE the increased IFN-I 
levels are found to not be correlated with depression and fatigue (Kellner et al., 
2010).  
Polymorphisms of the serotonin transporter gene promoter region (PR-5HTT) 
were studied in 96 SLE patients. Using the Hamilton depression rating scale 
(HDRS), depression scores were found to be associated with patients being 
homozygous for the short allele of the PR-5HTT gene (Xu et al., 2013). The 
methylation status of the region studied did not differ in patients with 
depression versus those without. In neuropsychiatric lupus, anti-ribosomal P 
antibodies (Ab) have been reported to occur more frequently in SLE patients 
with depression (Karimifar et al., 2013). In patients with a disease duration of 
less than two years, depression severity was correlated with anti-ribosomal P Ab 
levels. The antibody recognizes the carboxy 22 amino acids of the three large 
subunit ribosomal phosphoproteins, called P0, P1, and P2. Anti-ribosomal P Ab 
bind to neurons in the hippocampus, cingulate cortex, and the primary olfactory 
piriform cortex, and cause calcium influx and apoptosis (Bravo-Zehnder et al., 
2015). Intracerebroventricular injection of anti-ribosomal P Ab in mice induces a 
depression-like behavior and olfactory impairment. Mice displayed impaired 
passive avoidance (Katzav et al., 2014). In the pathophysiology of NPSLE, anti-
double stranded (ds)-DNA Ab may contribute to the involvement of the central 
nervous system. Some anti-native-DNA Ab cross-react with the GluN2A and 
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GluN2B subunits of the N-methyl-D-aspartate (NMDA) receptor for the 
neurotransmitter glutamate (Chang et al., 2015). Based on mouse experiments, 
cross-reacting antibodies may contribute to the neurocognitive impairment and 
other symptoms of NPSLE.  When injected with the 16/6 idiotypic antibodies, 
which recognize anti-ds-DNA Ab as well as brain glycoproteins and glycolipids, 
mice develop an impairment of spatial memory (Gono et al., 2013; Kivity et al., 
2013). 
 
3. Rheumatoid arthritis and depression-like symptoms 
 
In addition to its symptoms in affected joints, rheumatoid arthritis (RA) is 
associated with substantial mental health problems. In particular, depression has 
been documented to contribute significantly to impaired HRQoL, unemployment 
and loss of work productivity. Depression is very common in RA, the prevalence 
reported to be 13 to 42% (Isik et al., 2007). As reviewed recently, depression in 
RA provides an independent risk factor for cardiovascular disease and 
myocardial infarction, suicidal ideation and death, even after controlling for RA 
disease duration, disease activity, disability and pain (Margaretten et al., 2011). 
Depression in RA patients is most common in females and in younger age groups 
(Fifield et al., 1996). The risk to develop depression is highest in the first five 
years after RA diagnosis (Wang et al., 2014). Whilst pain is likely to contribute to 
the development of depression, the link between the severity of measurable 
parameters of arthritis and depression is less stringent. Since cytokines play a 
pivotal role in the synovial inflammation in RA and TNF blockers exert strong 
therapeutic effects, it may be suggested that the cytokine - brain connection is 
essential in depression in RA.  The hypothesis is supported by the observation of 
persistence of depression in patients with poor disease control by TNF blockers 
(Hider et al., 2009). However, studies investigating an association between 
depression in RA and increased CRP have yielded conflicting findings 
(Margaretten et al., 2011). In a recent study on RA (n= 102 with 75% females), 
using the Beck depression index II (BDI II) to assess depression, and the Health 
assessment questionnaire (HAQ) and the Disease activity score (DAS) to 
quantitate RA activity, a correlation of severity of depression and RA activity was 
identified (Imran et al., 2015). Somewhat in line with these data is the finding 
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that functional disability constitutes a significant risk factor for the occurrence of 
depression in RA (Katz and Yelin, 2001). Amelioration of depression symptoms 
in RA is linked to treatment-related RA control, positive psychological coping 
mechanisms, and social support (for review see (Margaretten et al., 2011)).  
 
4. Depression-like behavior in animal models of autoimmune diseases 
It is well established that rodents injected systemically or 
intacerebroventricularly with cytokines including TNF and IL-1 show an 
increase in sleep at times when mice are usually active (for review see (Imeri 
and Opp, 2009; Krueger, 2008)). NREM sleep was found to be increased in the 
dark phase of the 12 hr light-dark circadian cycle. This effect is associated with 
increase in body temperature, loss of body weight and development of 
depression-like behavioral changes). The same clinical picture emerges when 
mice are treated with activators of Toll-like receptors including the synthetic 
analogs of ds-RNA, namely Poly(I:C), lipopolysaccharide (LPS) extracted from 
gram-negative bacteria, or peptidoglycans. These experimental animal models 
present with depression-like behavior due to activation of the innate immune 
system. Animal models of depression-like behavior that are based on activation 
of the acquired immune system are less well established. In the following 
sections we discuss two models which do indeed involve or mimic effects of the 
aforementioned acquired immune mediated pathway. 
 
4.1 Depression-like behavior in Mrl/lpr mice 
 
MRL lymphoproliferation (MRL/lpr) strain mice develop a systemic autoimmune 
disease with arthritis, nephritis and neurological-psychiatric disease similar to 
SLE in humans. The mice show progressive lymphadenopathy due to the 
accumulation of double negative CD4-8-B220+ alpha beta+ T cells. The underlying 
defect involves the expression of a functionally inactive Fas receptor, which 
physiologically promotes activation induced cell death. Prior to the stage at 
which autoantibodies against DNA and nucleoproteins become detectable, 
MRL/lpr mice develop depression-like behavior including reduced activity in the 
forced swim-test and reduced preference for sweet solutions in the two-bottle 
sweet versus water test. (for review see: (Gulinello and Putterman, 2011)). Thus 
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studies on the pathophysiology of depression-like disease in the MRL/lpr 
autoimmune mouse offers potential new insights into the understanding of 
depression-like symptoms in SLE patients. 
 
4.2 Activation of CD40 leads to depression-like behavior in mice 
 
To study the aetio-pathophysiology of depression-like behavior in autoimmune 
diseases, we have developed a new mouse model, which is based on immune 
activation by CD40L-CD40 interactions. The CD40 ligand (CD40L) - CD40 
pathway is essential for the autoimmune response to self-antigens (Gast et al., 
2013). Mice with neutralization of this ligand-receptor pathway are protected 
from experimental autoimmune diseases such as experimental autoimmune 
encephalitis (EAE). Moreover patients with depression have increased plasma 
levels of soluble CD40 and CD40L (Leo et al., 2006; Neubauer et al., 2013). CD40L 
is expressed mainly by activated CD4+ T cells and binds to CD40 expressed on 
macrophages, B-lymphocytes and dendritic cells. CD40 activation by agonistic 
anti-CD40 monoclonal antibodies (mAb) induces synthesis of chemokines and 
cytokines including TNF, IL-18 and IFN type I and II. Immune activation is 
associated with multiorgan inflammation with severe necrotizing hepatitis, 
lymphadenopathy, splenomegaly, and depression-like behavior in the form of 
weight loss, decreased feeding, decreased activity and increased NREM sleep 
(Cathomas et al., 2015; Gast et al., 2013; Taraborrelli et al., 2011). These 
depression-like behaviors persist up to day 3. Furthermore, CD40 Ab also led to 
decreased operant motivation for and consumption of sweet-tasting saccharin 
solution up to day 7 and decreased fear conditioning of a tone to electroshock at 
day 5, indicating induction of reduced interest in reward and impaired 
learning/plasticity, respectively (Cathomas et al., 2015). These behavioral effects 
were coincident with increases in TNF as well as kynurenine and its down- 
stream catabolites in plasma and brain up to days 7-8. Co-injection of the TNF 
blocker etanercept with CD40 Ab prevented weight loss, decreased activity, 
increased sleep and reduced interest in reward, and markedly attenuated 
kynurenine pathway activation in plasma and brain. However, co-injection of an 
inhibitor of indoleamine 2-3, dioxygenase, the enzyme primarily responsible for 
tryptophan-to-kynurenine conversion, was without effect on either weight loss 
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or saccharin drinking (Cathomas et al., 2015). According to this mouse model, 
activation of TNF is necessary for causation of depression-like behavior in 
autoimmune disease. Extrapolating the findings to human suggests that 
symptoms such as decreased appetite, loss of interest-pleasure and cognitive 
impairments that are highly comorbid with autoimmine disorder have an aetio-
pathophysiology that begins with CD40-CD40L-TNF activation, whilst 
downstream factors remain to be elucidated. 
 
5. Abnormal clock gene system in autoimmune diseases and depression 
 
Circadian rhythms are mediated by clock genes, and thereby regulate 
metabolism and sleep-wake behavior (Eckel-Mahan and Sassone-Corsi, 2013; 
Franken and Dijk, 2009). The main transcription factors coordinating the 
circadian rhythms are CLOCK and BMAL1, which form heterodimers and activate 
expression of Period (Per), Cryptochrome (Cry) and of various clock controlled 
genes by binding to E-box motives (Dibner et al., 2010). Furthermore, CLOCK can 
be substituted by its paralog NPAS2 (Reick et al., 2001). The binding of 
CLOCK:BMAL1 to the E-box is regulated by positive and negative feedback 
mechanisms (Dibner et al., 2010). Patients with depression show sleep 
disturbances and an abnormal circadian regulation of hormones including 
cortisol and melatonin (Parry et al., 2008). Abnormal rhythms of expression of 
clock genes, due to effects of cytokines on transcription and posttranslational 
processes including chromatin remodelling, may play a role in depression. 
Increased risk for developing depression has been identified in individuals with 
polymorphisms carrying the CC genotype in Cry1 rs2287161 and the TT 
genotype in Tef rs738499 (Soria et al., 2010). An analysis of postmortem brain 
tissues from 55 normal controls and 34 patients with depression shows, in the 
patients, an abnormal phasing of circadian gene expression and potentially 
disrupted phase relationships between individual circadian genes (Li et al., 
2013). Also, the cyclic patterns were much weaker in the depression patients. 
 
Recent studies point to communication of the body clock and the immune system. 
For example the macrophage response to Salmonella is decreased in mice with 
an inactive clock gene (Bellet et al., 2013), and the extent of secretion of TNF and 
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IL-6 by LPS stimulated macrophages follows a circadian rhythm (Keller et al., 
2009). Besides effects of the circadian system on the immune response, the 
immune system also influences the circadian clock. TNF inhibits the expression 
of all three Period genes, of Cry-1 and -2 and of the PAR-bZip transcription 
factors Dbp, Tef and Hlf (Cavadini et al., 2007; Petrzilka et al., 2009). At least 
some of these effects are due to an interference with E-box-dependent 
transcription (Cavadini et al., 2007). Both TNF induced Twist1 expression and 
TNF-mediated inhibition of the cold-inducible RNA binding protein (CIRBP) are 
involved in immune mediated dysregulation of clock genes (Lopez et al., 2014; 
Meier et al., 2015). In light of the abnormal clock gene expression in depression, 
the polymorphisms in the Cry-1 and Tef genes associated with depression, and 
the dysregulated expression of clock genes in cells exposed to TNF and IL-1, we 
hypothesise that depression in autoimmune diseases may involve cytokine 
induced dysregulation of expression of clock genes. The hypothesis is supported 
by recent findings of abnormal expression of clock genes in rheumatoid arthritis, 
known for its high depression comorbidity (see above). When arthritis is 
induced in C57BL/6 mice by i.p. injection of anti-type II collagen mAb on day 1 
and LPS (50 µg) on day 2, the expression of Bmal1, Per2 and Dbp were decreased 
in the 24 hr cycle in spleen and the joints (Hashiramoto et al., 2010). When 
analyzing clock genes in cultured human rheumatoid synovial cells treated with 
TNF, suppression of the expression of  Per2, Dbp, Tef and Hlf was found (Yoshida 
et al., 2013). Recently, a loss of circadian rhythmicity in the expression of the 
clock genes Per2 and Per3 in CD14+ monocytes was identified in 
postmenopausal patients with rheumatoid arthritis (Spies et al., 2015). A down 
regulation of the aforementioned genes was also observed in a transcriptome 
analysis of genes expressed in the colon mucosa of patients with inflammatory 
bowel disease (Palmieri et al., 2015). The topic of clock genes, depression and 
autoimmune diseases has just started to become interesting. From first studies 
we conclude that the circadian expression of clock genes in autoimmune diseases 
is altered. It remains to be seen whether the defect is associated with behavioral 
abnormalities and/or abnormal immune regulation.  
 
6. Concluding remarks 
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The link between immune activation and depression-like behavior becomes 
evident from studies on injection of cytokines and their triggers such as LPS, 
PolyI:C and CD40 mAb in rodents. Autoimmune animal models, e.g. MRL/lpr 
mice or mice treated with agonistic CD40 mAb, support the hypothesis that 
immune effector pathways cause depression-like behavior. From the studies in 
SLE and RA outlined above, it can be concluded that in addition to organ specific 
symptoms arising due to autoimmune inflammation, depression or depression-
like symptoms are also a severe complication, which impairs quality of life. The 
reports on associations of immune activation with depression-like symptoms 
point to multiple underlying pathways impacting on these psychological states. 
Cytokines, autoantibodies and complement factors have all been shown to alter 
neuronal activity, either directly, by modulating the production of glutamate by 
microglia, or, in the case of TNF, by enhancing neuronal activity via activation of 
TNF receptors on astrocytes (Habbas et al., 2015; Piani et al., 1991). When taking 
one distinct immune effector pathway such as proinflammatory cytokines, their 
involvement in depression-like symptoms may not be clearly evident because 
other mechanisms e.g. in SLE, anti-NMDA receptor antibodies or anti-ribosomal 
P antibodies, may co-occur and, in contrast to cytokines, the production of 
autoantibodies may continue into the remission phase. In addition, the 
consequences of effects of cytokines and autoantibodies on brain circuitries may 
perpetuate beyond the active disease phase and cause persistence of depression-
like symptoms in an autonomic fashion in the absence of the triggering immune 
effector pathways. In addition to immunological mechanisms, many other 
variables including organ dysfunction (eg nephritis and hypertension in SLE), 
treatment including IFN type I and corticosteroids, social factors, functional 
disability and coping strategies may be confounding in studies aimed at 
demonstrating a (causal) relationship between immune activation and 
depression-like symptoms. Whilst it remains to be determined to what extent 
psychosocial-stress induced depression symptoms and depression-like 
symptoms in autoimmune diseases have common or separate pathophysiologies, 
it is clear that mood, motivation, fatigue and cognition are frequently disrupted 
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in autoimmune disorders, constitute a major component of the disease, and need 
to be the focus of research efforts designed to improve their treatment.   
 
 
Legend to Figures 
Figure 1 
Cytokines and the clock. Alterations of the circadian system may 
play a pivotal role in depressive-like behaviour. Cytokines interfere 
with the physiologic circadian oscillation of clock genes in the 
suprachiasmatic nucleus of the brain, which receives signals via the 
light-dark cycle. The oscillation of the peripheral clock is altered in 
autoimmune diseases in various organs including the liver and colon 
in hepatitis and colitis, respectively. This may cause abnormal 
expression of circadian genes. The clock system is also abnormal in 
lymphoid organs including the spleen and bone marrow. Thereby 
immune mediated effector pathways may be impaired. 
 
Figure 2 
Impaired expression of clock genes due to effects of 
proinflammatory cytokines. TNF and IL-1b decrease high 
amplitude expression of clock genes by inhibiting transcription of the 
cold-inducible RNA binding protein (CIRBP). Inhibition of CIRBP 
expression involves NF-kB activation. CIRBP enhances NF-kB 
expression and thereby eg. regulates TNF mediated apoptosis. In 
addition to CIRBP, Twist1 is also involved in altering clock gene 
expression. TNF and IL-1b induce Twist1, which interferes with the 
activation of E-box mediated transcription by CLOCK-BMAL1. This 
effect leads to impaired expression of the E-Box regulated clock 
genes Period-1, -2 and -3, the cryptochrome genes Cry-1 and-2, and 
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the PAR-bZip transcription factors Dbp, Tef and Hlf. However, recent 
studies on the expression of clock genes in colon and inflammatory 
monocytes of mice with DSS induced colitis do not support the in 
vitro findings of Twist1 to be involved in suppression of clock genes 
(Seles C., Strauss L, Rambousek L. and Fontana A. , manuscript in 
preparation). 
 
Figure 3 
Multiple pathways may lead to depression-like behavior in 
autoimmune diseases. Immune mediated tissue damage may lead 
to depression due to the development of hypoxia in heart and 
pulmonary failure, or due to the development of hypertension in 
kidney diseases. Depression is also caused by medication used to 
treat autoimmune diseases, such as treatment with interferon type 1 
in multiple sclerosis or corticosteroids in systemic lupus 
erythematosus. Recognition of self-antigens leads to activation of 
microglia and macrophages, and of astrocytes, which produce 
cytokines acting in an autocrine and paracrine manner. This step is 
followed by the release of molecules including excitatory amino acids, 
nitric oxide and reactive oxygen species, which alter synaptic 
signalling pathways and e.g. cause NMDA mediated synaptic 
activation. The latter effect is enhanced by impaired astrocyte 
glutamate detoxification. Neurotoxicity is amplified by oxidative 
stress and toxic effects of TNF on one hand, and poor neurotrophic 
support on the other. Autoantibodies to NMDA receptors and 
ribosomal P protein as detected in SLE may contribute to neuronal 
damage. 
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